Comparing bimatoprost and travoprost in black Americans

Current Medical Research and Opinion

Volumn 22, Issue 11, 2006, Pages 2175-2180

  Noecker, Robert J ^a   Earl, Melissa L ^b   Mundorf, Thomas K ^c   Silverstein, Steven M ^d   Phillips, Michael P ^c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Innovative Medical and Epidemiologic Data Solutions   (United States)

^c Silverstein Eye Center ^*

^d Silverstein Eye Centers   (United States)

Author keywords

Bimatoprost; Intraocular pressure (IOP); Ocular hypertension (OHT); Open angle glaucoma (OAG); Travoprost

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIMATOPROST; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; MIOTIC AGENT; PROSTAGLANDIN; TRAVOPROST;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BIOMICROSCOPY; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EYE DISEASE; FEMALE; HUMAN; INTRAOCULAR FOREIGN BODY; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; OPHTHALMOSCOPY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URTICARIA; VISUAL ACUITY;

ADMINISTRATION, TOPICAL; AFRICAN AMERICANS; AGED; AMIDES; CLOPROSTENOL; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; LIPIDS; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMOSCOPY; SINGLE-BLIND METHOD; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 33751237659     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X148418     Document Type: Article

References (21)

1. Marshall EC. Racial differences in the presentation of chronic open-angle glaucoma. J Amer Optometric Assoc 1989;60:760-7
2. Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of blindness in east Baltimore. N Engl J Med 1991;325:1412-7
3. Palmisano P, Hynes M, Mueller L. Glaucoma and race: a case for screening in Connecticut. Conn Med 2000;64:75-8
4. Sommer A, Tielsch JM, Katz J, et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. Arch Opthalmol 1991;109:1090-5
5. Javitt JC, McBean AM, Nicholson GA, et al. Undertreatment of glaucoma among black Americans. N Engl J Med 1991;325:1418-22
6. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 9. Comparison of glaucoma outcomes I black and white patients within treatment groups. Am J Ophthalmol 2001;132:311-20
7. Higginbotham EJ, Gordon MO, Beiser JA, et al. The Ocular Hypertension Treatment Study: topical medication delays or prevents primary open-angle glaucoma in African American individuals. Arch Ophthalmol 2004;122:813-20
8. Higginbotham E, Schuman J, Goldberg I, et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol 2002;120:1286-93
9. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472-84
10. Noecker RJ, Earl ML, Mundorf T, et al. Bimatoprost 0.03% versus travoprost 0.004% in black Americans with glaucoma or ocular hypertension. Adv Ther 2003;20:121-8
11. Cantor LB, Wudunn D, Cortes A, et al. Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Surv Ophthalmol 2004;49:S12-8
12. Cantor LB, Hoop JS, Morgan L. IOP-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Br J Ophthalmol 2006; July 6 [E-pub ahead of print]
13. Graham RH, Fusun Cardakli U. Glaucoma, suspect, adult. Available from http://www.emedicine.com/oph/topic127.htm [Last accessed 23 Aug 2006]
14. Netland PA, Robertson SM, Sullivan EK, et al. Response to travoprost in black and nonblack patients with open-angle glaucoma or ocular hypertension. Adv Ther 2003;20:149-56
15. The AGIS Investigators. The advanced glaucoma intervention study (AGIS): the relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429-40
16. Heijl A, Leske C, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression. Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-79
17. Quigley HA, Vitale S. Models of glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci 1997;38:83-91
18. Sherwood M, Brandt J. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol 2001;45:S361-8
19. Brandt J, VanDenburgh A, Chen K, et al. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology 2001;108:1023-31
20. Netland PA, Robertson SM, Sullivan EK, et al. Reponse to travoprost in black and nonblack patients with open-angle glaucoma or ocular hypertension. Adv Ther 2003;20:149-63
21. Parrish RK, Palmberg P, Sheu WP. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003;135:688-703